ProtoKinetix (PKTX) 10-K 30 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2015USD ($)shares
Document and Entity Information [Abstract]
Entity Registrant Name	ProtoKinetix, Inc.
Entity Central Index Key	1,128,189
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Trading Symbol	pktx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Public Float | $	$ 0
Entity Common Stock, Shares Outstanding | shares	0
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,015

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current Assets
Cash	$ 371,072	$ 317
Acounts receivable (Note 4)	8,023	$ 5,497
Prepaid expenses and deposits	397
Total current assets	379,492	$ 5,814
Intangible assets (Note 5)	70,260
Total assets	449,752	$ 5,814
Current Liabilities
Accounts payable and accrued liabilities	$ 45,388	270,893
Short-term loans (Note 6)		63,250
Convertible note payable (Note 7)		100,000
Total current liabilities	$ 45,388	434,143
Stockholders' Equity (Deficiency)
Common stock, $0.0000053 par value; 400,000,000 common shares authorized; 216,602,433 and 175,662,433 shares issued and outstanding for 2015 and 2014 respectively (Note 11)	$ 1,159	939
Common stock issuable; nil and 3,840,000 shares as at December 31, 2015 and 2014 respectively (Note 11)		20
Stock subscription received in advance (Note 11)		25,000
Common stock to be returned to treasury (Note 11)		(25,000)
Additional paid-in capital	$ 27,498,836	25,411,550
Accumulated deficit	(27,095,631)	(25,840,838)
Total stockholders' equity (deficiency)	404,364	(428,329)
Total liabilities and stockholders' equity (deficiency)	$ 449,752	$ 5,814

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common Stock, Par Value Per Share	$ 0.0000053	$ 0.0000053
Common Stock, Shares Authorized	400,000,000	400,000,000
Common Stock, Shares, Issued	216,602,433	175,662,433
Common Stock, Shares, Outstanding	216,602,433	175,662,433
Common stock issuable shares	0	3,840,000

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
EXPENSES
Amortization - intangible assets (Note 5)	$ 1,500
Consulting fees (Note 12)	125,000	$ 95,158
General and administrative	126,767	141,500
Interest	3,968	34,418
Professional fees (Note 12)	314,454	$ 133,769
Share-based compensation (Note 9)	531,486
Research and development	158,890	$ 13,750
Operating Income (Expenses)	(1,262,065)	(418,595)
OTHER ITEMS
Gain on settlement of short-term loan (Note 6)	$ 7,272	3,116
Gain on settlement of convertible note payable (Note 7)		192,000
Write off of deposit on sale (Note 3)		55,000
Loss for the year	$ (1,254,793)	$ (168,479)
Loss per common share (basic and diluted)	$ (0.01)	$ 0
Weighted average number of common shares outstanding (basic and diluted)	197,978,111	172,401,474

STATEMENT OF STOCKHOLDERS' EQUI

STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIENCY) - USD ($)	Common Stock [Member]	Common Stock Issuable shares	Additional Paid-in capital	Stock Subscriptions received in advance	Common stock to be returned to treasury	Accumulated Deficit	Total
Beginning Balance, Shares at Dec. 31, 2013	142,312,433	25,550,000
Beginning Balance, Amount at Dec. 31, 2013	$ 763	$ 135	$ 25,028,311	$ 25,000		$ (25,672,359)	$ (618,150)
Issuance of common stock for services, shares	25,600,000	(25,550,000)
Issuance of common stock for services, amount	$ 136	$ (135)	999				1,000
Fair value of compensatory warrants issued			40,300				40,300
Issuance of common stock to settle short-term loans, shares	2,500,000
Issuance of common stock to settle short-term loans, amount	$ 13		24,987				25,000
Issuance of common stock pursuant to private placement offering, shares	5,000,000
Issuance of common stock pursuant to private placement offering, amount	$ 25		99,975				$ 100,000
Common stock issued in error, shares	250,000
Common stock issued in error, amount	$ 2		24,998	(25,000)
Common stock to be returned to treasury, amount				25,000	$ (25,000)
Common stock issuable on settlement of convertible note payable, shares		3,840,000
Common stock issuable on settlement of convertible note payable, amount		$ 20	191,980				$ 192,000
Net loss for the year						(168,479)	(168,479)
Ending Balance, Shares at Dec. 31, 2014	175,662,433	3,840,000
Ending Balance, Amount at Dec. 31, 2014	$ 939	$ 20	25,411,550	25,000	(25,000)	(25,840,838)	(428,329)
Issuance of common stock for services, shares	1,000,000
Issuance of common stock for services, amount	$ 6		39,994				$ 40,000
Common stock to be returned to treasury, shares	(250,000)
Common stock to be returned to treasury, amount	$ (1)		(24,999)		$ 25,000
Common stock issuable on settlement of convertible note payable, shares	3,840,000	(3,840,000)
Common stock issuable on settlement of convertible note payable, amount	$ 20	$ (20)
Issuance of common stock pursuant to private placement offering, shares	15,000,000
Issuance of common stock pursuant to private placement offering, amount	$ 80		374,920				$ 375,000
Issuance of common stock pursuant to private placement offering, shares	2,500,000
Issuance of common stock pursuant to private placement offering, amount	$ 13		124,987				$ 125,000
Issuance of common stock pursuant to private placement offering, shares	250,000
Issuance of common stock pursuant to private placement offering, amount	$ 1		24,999	$ (25,000)
Issuance of common stock pursuant to private placement offering, shares	1,250,000
Issuance of common stock pursuant to private placement offering, amount	$ 7		99,993				$ 100,000
Issuance of common stock pursuant to private placement offering, shares	312,500
Issuance of common stock pursuant to private placement offering, amount	$ 2		24,998				25,000
Issuance of common stock pursuant to private placement offering, shares	375,000
Issuance of common stock pursuant to private placement offering, amount	$ 2		29,998				30,000
Issuance of common stock pursuant to private placement offering, shares	625,000
Issuance of common stock pursuant to private placement offering, amount	$ 3		49,997				50,000
Issuance of common stock for services, shares	300,000
Issuance of common stock for services, amount	$ 2		20,998				21,000
Issuance of common stock pursuant to settle promissory note, shares	1,250,000
Issuance of common stock pursuant to settle promissory note. amount	$ 7		99,993				100,000
Issuance of common stock pursuant to private placement offering, shares	625,000
Issuance of common stock pursuant to private placement offering, amount	$ 3		24,997				25,000
Issuance of common stock for services and other value, shares	300,000
Issuance of common stock for services and other value, amount	$ 2		14,998				15,000
Issuance of units pursuant to private placement offering, shares	5,000,000
Issuance of units pursuant to private placement offering, amount	$ 27		199,973				200,000
Fair value of compensatory options issued			531,486				531,486
Fair value of compensatory warrants issued			25,000				25,000
Issuance of units pursuant to private placement offering, shares	1,562,500
Issuance of units pursuant to private placement offering, amount	$ 8		124,992				125,000
Exercise of warrants, shares	5,000,000
Exercise of warrants, amount	$ 27		199,973				200,000
Issuance of common stock for services, shares	2,000,000
Issuance of common stock for services, amount	$ 11		99,989				100,000
Net loss for the year						(1,254,793)	(1,254,793)
Ending Balance, Shares at Dec. 31, 2015	216,602,433
Ending Balance, Amount at Dec. 31, 2015	$ 1,159		$ 27,498,836			$ (27,095,631)	$ 404,364

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS USED IN OPERATING ACTIVITIES
Net loss for the year	$ (1,254,793)	$ (168,479)
Adjustments to reconcile net loss to cash used in operating activities:
Gain on settlement of convertible note payable		(192,000)
Accretion of short-term loan		$ 2,630
Amortization - intangible assets	$ 1,500
Issuance and amortization of common stock for services	176,000	$ 8,667
Fair value of compensatory options granted	$ 531,486
Fair value of compensatory warrants granted		$ 40,300
Gain on settlement of short-term loans	$ (7,272)	(3,116)
Write-off of deposit on sale		(55,000)
Changes in operating assets and liabilities:
Accounts receivable	$ (2,526)	(5,378)
Prepaid expenses and deposits	(397)	14,794
Accounts payable and accrued liabilities	(18,233)	128,334
Net cash used in operating activities	$ (574,235)	(229,248)
CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES
Deposit on sale		$ 30,000
Purchase of intangible assets	$ (46,760)
Net cash from (used in) investing activities	$ (46,760)	$ 30,000
CASH FLOWS FROM FINANCING ACTIVITIES
Short-term loan proceeds, net		20,000
Repayment of short-term loan	$ (43,250)	(23,500)
Convertible note proceeds		100,000
Issuance of common stock for cash	$ 1,035,000	100,000
Net cash from financing activities	991,750	196,500
Net change in cash	370,755	(2,748)
Cash, beginning of year	317	3,065
Cash, end of year	$ 371,072	$ 317
Cash paid for interest
Cash paid for income taxes
Supplementary information - non-cash transactions:
Common stock issued for consulting services	$ 236,000	$ 1,000
Common stock issued to settle short-term loans, accounts payable and accrued liabilities	$ 220,000	25,000
Short-term loans converted to accounts payable		$ 60,250
Common stock returned to treasury	$ 25,000
Common stock issued for past subscriptions	25,000
Common stock issued to settle promissory note	100,000
Fair value of warrants issued for intangible asset	$ 25,000

1. Basis of Presentation - Goin

1. Basis of Presentation - Going Concern Uncertainties	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements [Abstract]
Basis of Presentation - Going Concern Uncertainties	ProtoKinetix, Inc. (the "Company"), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999. The Company is a medical research company whose mission is the advancement of human health care. The Company is currently researching the benefits and feasibility of synthesized Antifreeze Glycoproteins ("AFGP") or anti-aging glycoproteins, trademarked AAGP. During the year ended December 31, 2015, the Company acquired certain patents and rights for cash consideration of $30,000 (25,000 Euros), as well as additional patent applications for cash consideration of $10,000 and 6,000,000 share purchase warrants with a fair value of $25,000 (Note 5). A Cease Trade Order (“CTO”) was issued in respect of the Company’s securities by the British Columbia Securities Commission (“BCSC”) on May 9, 2013 based on the Company’s failure to file annual financial statements for the year ended December 31, 2012 by the deadline of April 1, 2013. The Company has since completed all of the required filings for annual and interim periods and received a full Revocation Order from the BCSC during the year ended December 31, 2015. The Company's financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern. The Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit at December 31, 2015. These factors raise substantial doubt about the Company's ability to continue as a going concern. The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities. Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective. Management is presently engaged in seeking additional working capital through equity financing or related party loans. The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.

2. Summary of Significant Accou

2. Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements [Abstract]
Summary of Significant Accounting Policies	Basis of Presentation The accompanying financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and are expressed in United States dollars. Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued and deferred income taxes. Cash Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time. Fair Value of Financial Instruments Financial instruments, including cash, accounts payable and accrued liabilities, short-term loans and convertible note payable are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions) Level 1 inputs are used to measure cash. At December 31, 2015 there were no other assets or liabilities subject to additional disclosure. Income Taxes The Company accounts for income taxed following the assets and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled. Intangible assets – patent and patent application costs The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred. As at December 31, 2015, the Company does not hold any intangible assets with indefinite lives. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company’s patents, whereas no amortization has been recognized on the patent application costs as at December 31, 2015. Research and Development Costs Research and development costs are expensed as incurred. Loss per Share and Potentially Dilutive Securities Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 14,600,000 stock options (December 31, 2014 - nil), 8,700,000 warrants (December 31, 2014 – 5,200,000) and debt convertible into nil common shares (December 31, 2014 – 400,000) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses. Share-Based Compensation The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model. The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance. The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 “Stock-Based Transactions with Nonemployees””, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period. Common stock Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty’s performance is complete. Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects. Related Party Transactions A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. Recent Accounting Pronouncements In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessment of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is substantial doubt about the entity’s ability to continue as a going concern. The requirement is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s financial statements.

3. Sales Agreement with Intrepi

3. Sales Agreement with Intrepid Innovations Corporation	12 Months Ended
	Dec. 31, 2015
Sales Agreement With Intrepid Innovations Corporation
Sales Agreement with Intrepid Innovations Corporation	During the year ended December 31, 2013, the Company entered into an agreement with Intrepid Innovations Corporation (“Intrepid”) to sell the exclusive rights for the application of the AAGP molecule. The total purchase price for the exclusive rights to the application was $2,500,000 and was to be paid as follows: • $25,000 cash deposit (received); • $25,000 paid by cash on or before April 22, 2014 as a balance of the transaction deposit (received); • Six monthly payments of $25,000 on or before May 22, June 22, July 22, August 22, September 22 and October 22, 2014 ($5,000 received); and • $2,300,000 paid by the issuance of 3,500,000 restricted shares of the buyer as payment of the outstanding balance. These shares can be redeemed by a cash payment at any time within the first 6 months of the effective date of this agreement. Once the Company had received $2,500,000 in total through payment, sale of the shares and through the redemption of the shares, any surplus shares would have been returned to Intrepid. In the event that the total payment had not totaled $2,500,000, Intrepid would pay the difference to the Company no later than 13 months after the effective date of this agreement. The agreement was terminated during the year ended December 31, 2014 due to non-payment of the agreed to amounts. The amounts advanced are non-refundable in accordance with the agreement and as at December 31, 2014, the Company recognized a gain on deposit on sale in the amount of $55,000 to the statement of operations.

4. Accounts Receivable

4. Accounts Receivable	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements [Abstract]
Accounts Receivable	Accounts receivable consists of refundable sales tax paid on purchases made in Canada.

5. Intangible Assets

5. Intangible Assets	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	During the year ended December 31, 2015, the Company entered into an Assignment of Patents and Patent Application (effective January 1, 2015) (the “Patent Assignment”) with the Institut National des Sciences Appliquees de Rouen (“INSA”) for the assignment of certain patents and all rights associated therewith (the “Patents”). The Company and INSA had previously entered into a licensing agreement for the Patents in August 2004. The Patent Assignment transfers all of the Patents and rights associated therewith to the Company upon payment to INSA in the sum of $30,000 (25,000 Euros) (paid). During the year ended December 31, 2015, the Company recorded $1,500 in amortization expense associated with the Patents. During the year ended December 31, 2015, the Company entered into a Technology Transfer Agreement with Grant Young for the assignment of his 50% ownership of certain patents and all rights associated therewith (the "Patent Application Rights"). In exchange for the Patent Application Rights, the Company agreed to pay $10,000 (paid) and to issue 6,000,000 warrants (issued) to purchase shares of the Company's common stock at an exercise price of $0.10 per share for a period of five years. The Patent Application Rights had a total fair value of $35,000, which was allocated as $10,000 to the cash consideration paid, with the remaining $25,000 being allocated to the warrant component of the overall consideration. The Company incurred an additional $6,760 in direct costs relating to the Patent Application Rights. The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty further discussed in Note 13(c). No amortization was recorded on the Patent Application Rights to December 31, 2015.

6. Short-Term Loans

6. Short-Term Loans	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements [Abstract]
Short-Term Loans	During the year ended December 31, 2013, the Company received a loan of $20,000. The loan was to be repaid by November 8, 2014, along with $10,000 in interest. In addition, the Company issued 500,000 warrants to the lender, exercisable at $0.25 for a period of 5 years. The proceeds of the loan were allocated between the debt and warrants based on a relative fair value approach, which bifurcates between the values of the two securities at the time of issuance. Using this approach, the fair value of the warrants was estimated at $4,400, with the remaining $15,600 being allocated to the debt portion; to be accreted to its settlement value over the term of the loan. The loan was settled in August 2014 for $23,500 (Note 7), and total accretion for the year ended December 31, 2014 was $2,630, while accrued interest on the loan principal totaled $7,653 as at the settlement date. A gain on settlement of $3,116 was recognized based on a settlement payment made totaling $23,500 (Note 7). During the year ended December 31, 2014, the Company issued a total of 2,500,000 units to settle $25,000 in short-term loans (Note 11). During the year ended December 31, 2015, a total of $60,250 in short-term loans were paid directly by the Company’s CEO. The amount was owing to the CEO and had been included in accounts payable and accrued liabilities as at December 31, 2014 as no formal loan agreements had been completed. These amounts were settled in part of the financing detailed in Note 11(c). The remainder of the short-term loans in the amount of $nil (December 31, 2014 - $63,250) were unsecured, non-interest bearing and were repayable on demand.

7. Convertible Note Payable

7. Convertible Note Payable	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements [Abstract]
Convertible Note Payable	On July 1, 2011, the Company executed a loan agreement under which the Company issued to a corporation an 8% convertible promissory note in exchange for $300,000. The note holder had the right to demand payment of outstanding principal and interest at any time with a 30-day grace period. The note was due and payable no later than June 30, 2016, and was convertible into shares of the Company's common stock at $0.025 per share. No beneficial conversion feature was applicable to this convertible note. During the year ended December 31, 2014, the Company and the corporation commenced discussions in regards to the settlement of the convertible note through extinguishment. A settlement agreement was finalized during the year ended December 31, 2015, but the Company has accounted for the transaction as at December 31, 2014. The settlement agreement stipulated that the convertible note plus accrued interest of $84,000 (included in accounts payable and accrued liabilities as at December 31, 2014) was to be settled through the issuance of 3,840,000 shares of the Company’s common stock. The fair value of the shares was determined to be $192,000 ($0.05 per share) and the Company recognized a gain on settlement in the amount of $192,000 as at December 31, 2014 (Note 11). The settlement agreement also stipulated the payment of $161,750 to the corporation to settle other amounts included in accounts payable and accrued liabilities and short-term loans, all of which has been paid as at December 31, 2015. On June 17, 2014, the Company executed a loan agreement under which the Company issued an 8% convertible promissory note in exchange for an initial amount of $10,000, with the ability to be increased to $100,000, to the Company`s President and CEO. During the year ended December 31, 2014, additional amounts totaling $90,000 were advanced, $23,500 of which was paid directly to settle certain short-term loans outstanding (Note 6). The note holder had the right to demand payment of outstanding principal and interest at any time with a 30-day grace period. The note was due and payable no later than December 31, 2015, and was convertible into shares of the Company's common stock at $0.25 per share. No beneficial conversion feature was applicable to this convertible note. On July 1, 2015, the Company`s board of directors approved an adjustment to the conversion price from $0.25 to $0.08. During the year ended December 31, 2015, the Company issued 1,250,000 shares of the Company’s common stock at the adjusted conversion price of $0.08 per share to settle the promissory note. A gain of $7,272 was recognized associated with interest forgiven on the note.

8. Common Shares Issued for Ser

8. Common Shares Issued for Services	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements [Abstract]
Common Shares Issued for Services	During the years ended December 31, 2015 and 2014, the Company issued shares of common stock for services and other value rendered as follows: 2015 Number Value Total February 2015 1,000,000 $ 0.04 $ 40,000 June 2015 100,000 0.07 7,000 September 2015 100,000 0.07 7,000 September 2015 300,000 0.05 15,000 December 2015 100,000 0.07 7,000 December 2015 2,000,000 0.05 100,000 3,600,000 $ 176,000 2014 Number Value Total January 2014 25,550,000 $ 0.01 $ 255,500 June 2014 50,000 0.02 1,000 25,600,000 $ 256,500

9. Stock Options

9. Stock Options	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements [Abstract]
Stock Options	On July 1, 2015, the Board of Directors of the Company adopted the 2015 Stock Option and Stock Bonus Plan (the “Plan”). The Board of Directors adopted this plan as it anticipates utilizing equity compensation as part of its ongoing standard corporate operations and in connection with its contemplated activities going forward. Under the Plan, the lesser of: (i) 20,000,000 shares; or (ii) 10% of the total number of the Company’s common shares outstanding are reserved to be issued upon the exercise of options or the grant of stock bonuses. As such, the Plan is subject to an absolute cap of 20,000,000 shares. The Plan includes two types of options; options intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended are referred to as incentive options, and options which are not intended to qualify as incentive options are referred to as non-qualified options. As of December 31, 2015, 1,600,000 options and 2,000,000 shares of common stock have been granted under the Plan. The Plan is administered by the Board of Directors, or a committee appointed by the Board of Directors. In addition to determining who will be granted options or stock bonuses, the committee has the authority and discretion to determine when options and bonuses will be granted and the number of options and bonuses to be granted. The committee also may determine a vesting and/or forfeiture schedule for bonuses and/or options granted, the time or times when each option becomes exercisable, the duration of the exercise period for options and the form or forms of the agreements, certificates or other instruments evidencing grants made under the Plan. The committee may determine the purchase price of the shares of common stock covered by each option and determine the fair market value per share. The committee also may impose additional conditions or restrictions not inconsistent with the provisions of the Plan. The committee may adopt, amend and rescind such rules and regulations as in its opinion may be advisable for the administration of the Plan. In the event that a change, such as a stock split, is made in the Company’s capitalization which results in an exchange or other adjustment of each share of common stock for or into a greater or lesser number of shares, appropriate adjustments will be made to unvested bonuses and in the exercise price and in the number of shares subject to each outstanding option. The committee also may make provisions for adjusting the number of bonuses or underlying outstanding options in the event the Company effects one or more reorganizations, recapitalizations, rights offerings, or other increases or reductions of shares of its outstanding common stock. Options and bonuses may provide that in the event of the dissolution or liquidation of the Company, a corporate separation or division or the merger or consolidation of the Company, the holder may exercise the option on such terms as it may have been exercised immediately prior to such dissolution, corporate separation or division or merger or consolidation; or in the alternative, the committee may provide that each option granted under the Plan shall terminate as of a date fixed by the committee. The exercise price of any option granted under the Plan must be no less than 100% of the “fair market value” of the Company’s common stock on the date of grant. Any incentive stock option granted under the Plan to a person owning more than 10% of the total combined voting power of the common stock must be at a price of no less than 110% of the fair market value per share on the date of grant. The exercise price of an option may be paid in cash, in shares of the Company’s common stock or other property having a fair market value equal to the exercise price of the option, or in a combination of cash, shares, other securities and property. The committee determines whether or not property other than cash or common stock may be used to purchase the shares underlying an option and shall determine the value of the property received. Stock option transactions are summarized as follows: Number of Weighted Average Weighted Average Weighted Average $ $ (Years) Outstanding, December 31, 2013 and 2014 - - - Options granted 14,600,000 0.05 0.03 Outstanding, December 31, 2015 14,600,000 0.05 0.03 3.09 The fair values of the stock options granted during the year ended December 31, 2015 were estimated using the Black-Scholes Option Pricing Model. The weighted average assumptions used in the pricing model for these options are as follows: For the year ended December 31, 2015 Risk-free interest rate 0.90 % Dividend yield 0.00 % Expected stock price volatility 125.00 % Expected forfeiture rate 0.00 % Expected life 4.50 years The following non-qualified stock options were outstanding and exercisable at December 31, 2015: Expiry date Exercise Price Number of Outstanding Number of Options $ March 12, 2016 0.10 1,000,000 750,000 February 25, 2017 0.04 2,000,000 - February 24, 2018 0.05 1,000,000 1,000,000 February 25, 2020 0.04 4,000,000 4,000,000 February 28, 2020 0.04 5,000,000 5,000,000 June 30, 2017 0.10 1,000,000 1,000,000 June 30, 2018 0.10 600,000 600,000 14,600,000 12,350,000 As at December 31, 2015, the aggregate intrinsic value of the Company’s stock options is $350,000 (December 31, 2014 – $nil). The weighted average fair value of stock options granted during the year is $0.05 (2014 - $nil).

10. Warrants

10. Warrants	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements [Abstract]
Warrants	Warrant transactions for the years ended December 31, 2014 and 2015 are summarized as follows: Number of Weighted Balance, December 31, 2013 21,300,000 $ 0.03 Issued 4,700,000 0.07 Expired (20,800,000 ) 0.02 Balance, December 31, 2014 5,200,000 0.09 Issued 11,000,000 0.07 Expired (2,500,000 ) 0.05 Exercised (5,000,000 ) 0.04 Balance, December 31, 2015 8,700,000 $ 0.11 The following warrants were outstanding and exercisable as at December 31, 2015: Number of Warrants Exercise Price ($) Expiry Date 1,600,000 0.10 January 1 , 2016* 300,000 0.05 January 1 , 2016* 300,000 0.15 January 1 , 2016* 500,000 0.25 November 8, 2018 6,000,000 0.10 April 22, 2020 8,700,000 *Subsequent to the year ended December 31, 2015, these warrants expired unexercised.

11. Stockholders' Equity (Defic

11. Stockholders' Equity (Deficiency)	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements [Abstract]
Stockholders' Equity (Deficiency)	The Company is authorized to issue 400,000,000 (December 31, 2014 – 400,000,000) shares of $0.0000053 par value common stock. Each holder of common stock has the right to one vote but does not have cumulative voting rights. Shares of common stock are not subject to any redemption or sinking fund provisions, nor do they have any preemptive, subscription or conversion rights. Holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of December 31, 2015 (December 31, 2014 - $nil). During the year ended December 31, 2015, the Company: a) Issued 1,000,000 shares of common stock with a fair value of $40,000 ($0.04 per share) pursuant to a directorship agreement entered into on February 25, 2015 (Note 12). b) Issued 3,840,000 shares of common stock with a fair value of $192,000 ($0.05 per share) pursuant to a settlement agreement completed on March 2, 2015 with a convertible note holder (Note 7). c) Issued 15,000,000 shares of common stock at $0.025 per share pursuant to a stock subscription agreement with the Company’s President and CEO. The proceeds of $375,000 were offset by $150,000 owing to the President and CEO as previously included in accounts payable and accrued liabilities and $20,000 owing in short-term loans (Note 6). The remaining proceeds of $205,000 were received in cash during the year ended December 31, 2015. d) Issued 2,500,000 shares of common stock to two investors (one of which was the President and CEO of the Company) at $0.05 per share for gross proceeds of $125,000. e) Cancelled 250,000 shares of common stock that were returned to treasury. The shares had been issued in error and the Company had accounted for the return as “Common stock to be returned to treasury” as at December 31, 2014. f) Issued 250,000 shares of common stock pursuant to a stock subscription received during the year ended December 31, 2010. g) Issued 1,250,000 shares of common stock at $0.08 per share for gross proceeds of $100,000 pursuant to private placement offering. h) Issued 312,500 shares of common stock at $0.08 per share for gross proceeds of $25,000 pursuant to private placement offering. i) Issued 375,000 shares of common stock at $0.08 per share for gross proceeds of $30,000 pursuant to private placement offering. j) Issued 625,000 shares of common stock at $0.08 per share pursuant to a stock subscription agreement with the Company’s President and CEO. The proceeds of $50,000 were offset in their entirety by certain amounts owing to the President and CEO as previously included in accounts payable and accrued liabilities. k) Issued 300,000 shares of common stock with a fair value of $21,000 ($0.07 per share) pursuant to a consulting agreement entered into on March 1, 2015 (Note 13). l) Issued 1,250,000 shares of the Company’s common stock at an adjusted conversion price of $0.08 per share on conversion of a promissory note (Note 7). m) Issued 625,000 shares of common stock at $0.04 per share for gross proceeds of $25,000 pursuant to a stock subscription agreement with the Company’s President and CEO. n) Issued 300,000 shares of common stock with a fair value of $15,000 ($0.05 per share) pursuant to a settlement agreement entered into on September 29, 2015 for services and other value received. o) Issued 5,000,000 units at $0.04 per unit or gross proceeds of $200,000. Each unit is comprised of one share of common stock and one share purchase warrant exercisable at a price of $0.04 until December 28, 2015. p) Issued 1,562,500 shares of common stock at $0.08 per share for gross proceeds of $125,000 pursuant to a private placement offering. q) Issued 5,000,000 shares of common stock at $0.04 per share or gross proceeds of $200,000 upon the exercise of warrants. r) Issued 2,000,000 shares of common stock with a fair value of $100,000 ($0.05 per share) as a bonus to the Company’s President and CEO (Note 12). During the year ended December 31, 2014, the Company: a) Issued 25,550,000 shares of restricted common stock for consulting, research and investor relations services provided during the year ended December 31, 2013. The value of these shares was $255,500 and had been accrued as common stock issuable as at December 31, 2013. b) Issued 50,000 shares of common stock to an individual for website services provided during year ended December 31, 2014. The value of these shares was $1,000 and was recorded as general and administrative expense. c) Issued 2,200,000 compensatory warrants with a fair value of $40,300 (Note 10). d) Issued 2,500,000 units to settle a portion of the short-term loans totaling $25,000. Each unit consists of one share of common stock and one warrant exercisable at a price of $0.05 for a period of 1 year expiring on February 18, 2015 (Note 10). e) Issued 5,000,000 units at $0.02 per unit to a related party for gross proceeds of $100,000. f) Issued 250,000 shares of common stock in error. Management of the Company had believed that they had issued the shares pursuant to share subscriptions previously received during the year ended December 31, 2010. The shares were issued to the wrong individual and were returned to treasury and cancelled during the year ended December 31, 2015. Management has identified the original subscriber to the 2010 financing and issued the 250,000 shares to this individual during the year ended December 31, 2015.

12. Related Party Transactions

12. Related Party Transactions and Balances	12 Months Ended
	Dec. 31, 2015
Related Party Transactions And Balances
Related Party Transactions and Balances	During the year ended December 31, 2015, the Company: a) Entered into a directorship agreement effective February 25, 2015 with a newly appointed director of the Company. Pursuant to the agreement, the director was issued 1,000,000 shares of common stock as an engagement fee (Note 11) and will be entitled to a compensatory service fee for legal services over and above a mandatory 10 hours per month requirement stipulated in the agreement. Service fees for the year ended December 31, 2015 totaled $12,747 (2014 - $nil). The shares were issued at a total value of $40,000 ($0.04 per share). The director also received 1,000,000 stock options on signing (Note 9) exercisable into common shares of the Company for a period of 3 years at a price of $0.05 per share. The director resigned from the board but has been appointed to the Company’s Business and Scientific Advisory Board as a consultant. b) Entered into a consulting agreement dated March 30, 2015 (effective January 1, 2015) with the Company’s President and CEO whereby he will be compensated at a nominal amount of $1 for services through to December 31, 2015. The agreement also stipulates a termination fee that would pay the Company’s President and CEO $100,000 if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 plus 2.5% of the aggregate transaction value of the change of control. During the year ended December 31, 2015, the President and CEO was issued 2,000,000 shares of common stock with a total value of $100,000 ($0.05 per share) as a bonus issuance. c) Entered into a consulting agreement dated March 30, 2015 (effective January 1, 2015) with the Company’s CFO whereby she will be compensated at a monthly fee of $4,000 for services through to December 31, 2018 ($4,000 per month for fiscal 2015, then increased by not less than 5% each year thereafter). Effective June 1, 2015, the monthly fee was increased to $4,200. A total of $49,400 was paid or accrued to the Company’s CFO during the year ended December 31, 2015 (2014 - $12,000). She is also entitled (as of February 26, 2015) to 4,000,000 stock options (Note 9) exercisable into common shares of the Company for a period of 5 years at a price of $0.04 per share. The options will vest monthly in tranches of 400,000 over 10 months. She will also be entitled to an additional 2,000,000 stock options exercisable for a period of 2 years at a price of $0.04 per share that will vest only upon a change in control. If terminated without cause, the agreement also stipulates a termination fee that would pay the Company’s CFO three times her monthly consulting fee in effect as of the date of termination or if terminated without cause after January 1, 2016, six times her monthly consulting fee in effect as of the date of termination. In the case of termination upon a change of control event, the termination fee would be equal to two times the amount that she would receive as if terminated without cause. Subsequent to December 31, 2015, the consulting agreement was amended (Note 15). d) Entered into a directorship agreement effective July 1, 2015 with a newly appointed director of the Company. Pursuant to the agreement, the director was issued 1,000,000 stock options on signing (Note 9) exercisable into common shares of the Company for a period of 2 years at a price of $0.10 per share. The options vested in monthly installments of 166,666 options beginning July 31, 2015 with the final 166,670 options vesting on December 31, 2015. e) During the year ended December 31, 2014, the Company’s former President, CEO and CFO was paid total consulting fees of $45,975. During the year ended December 31, 2015, the Company paid $10,000 in penalties associated with the revocation of the CTO on behalf of the former officer. f) Recognized $194,032 (2014 - $nil) in share-based compensation associated with stock options granted to key management personnel. As at December 31, 2015 and December 31, 2014, the following amounts are due to related parties: December 31, 2015 December 31, 2014 Clarence Smith (CEO) Accounts payable and accrued liabilities $ 327 $ 129,592 Short-term loans $ nil $ 20,000 Convertible note payable $ nil $ 100,000 Susan Woodward (CFO) Accounts payable and accrued liabilities $ nil $ 12,000 Amounts included in accounts payable and accrued liabilities are non-interest bearing, unsecured and repayable on demand. Amounts included in short-term loans and convertible note payable had terms disclosed in Notes 6 and 7 respectively.

13. Commitments and Contingency

13. Commitments and Contingency	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingency	During the year ended December 31, 2015, the Company: a) Entered into a consulting agreement effective March 1, 2015, whereby the Company would pay the consultant $10,000 on signing (paid) and $5,000 per month for an initial term of 1 year for providing research and development services. The consultant is also entitled to 5,000,000 stock options within 30 days of the consulting agreement (Note 9), with each stock option exercisable into a common share at a price of $0.04 for a period of 5 years. The stock options vested 25% on grant and 25% every 3 months thereafter. Subsequent to December 31, 2015, the consulting agreement was amended (Note 15). b) Entered into a consulting agreement effective March 1, 2015, whereby the Company would pay the consultant $2,700 per month for an initial term of 1 year for providing public relations services. The consultant is also entitled to 400,000 shares of common stock, which will be issued at a rate of 25% (100,000 shares) every 3 months over the term of the agreement (100,000 shares issued subsequent to December 31, 2015 (Note 15). The consultant is also entitled to 1,000,000 stock options on signing (Note 9), with each stock option exercisable into a common share at a price of $0.10 for a period of 5 years. The stock options will vest at the rate of 25% every 3 months over the term of the agreement. c) Entered into a royalty agreement with the Governors of the University of Alberta (the “University”) whereby the University had developed certain intellectual property (the “Additional Patent Rights”) in conjunction with and by permission of the Company employing patented intellectual property of the Company. The agreement assigns the Additional Patent Rights to the Company in return for 5% of any future gross revenues (the “Royalty”) derived from products arising from the Patent Rights. The Company will have the right and option for two years from the earlier of September 1, 2015 or the first date that the University publishes its research related to the Additional Patent Rights to buy out all of the University’s Royalty for consideration of the aggregate sum of CDN $5,000,000. d) Entered into a consulting agreement effective May 1, 2015, whereby the Company would pay the consultant $4,000 per month for an initial term of 1 year for providing research and development services. e) Entered into a consulting agreement for business development services effective July 1, 2015. The consultant was granted 600,000 stock options exercisable into common shares of the Company at a price of $0.10 per share for a period of 3 years. The options will vest in monthly installments of 100,000 options beginning July 31, 2015 with the final vesting on December 31, 2015. f) The Company was delinquent in filing certain income tax returns with the U.S. Internal Revenue Service and reports disclosing its interest in foreign bank accounts on form TDF 90-22.1, “Report of Foreign Bank and Financial Accounts” (“FBARs”). In September 2015, the Company filed the delinquent income tax returns and has sought waivers of any penalties under the IRS Offshore Voluntary Disclosure Program for late filing of the returns and FBARs. Under the program, the IRS has indicated that it will not impose a penalty for the failure to file delinquent income tax returns if there are no underreported tax liabilities. The Company may be liable for civil penalties for certain tax years in an indeterminate amount for not complying with the FBAR reporting and recordkeeping requirements. No claim has been asserted by the U.S. Internal Revenue Service; before any claim is expressly asserted the Company intends to cooperate with the Internal Revenue Service to minimize any liability. The Company is unable to determine the amount of any penalties that may be assessed at this time.

14. Income Taxes

14. Income Taxes	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements [Abstract]
Income Taxes	As a Nevada corporation, the Company is liable for taxes in the United States. As of December 31, 2015, the Company did not have any income for tax purposes and therefore, no tax liability or expense has been recorded in these financial statements. The Company has tax losses of approximately $26,400,000 (2014 - $25,800,000) to reduce future taxable income. The tax losses expire in years starting from 2028. The deferred tax asset associated with the tax loss carry forward is approximately $9,000,000 (2014 - $8,800,000). The Company has provided a full valuation allowance against the deferred tax asset since it is more likely than not that the asset will not be realized. The difference between the Company's statutory income tax rate of (34%) and its effective rate of zero is primarily attributable to the valuation allowance provided on deferred taxes arising from net operating loss carryforwards.

15. Subsequent Events

15. Subsequent Events	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements [Abstract]
Subsequent Events	Subsequent to the year ended December 31, 2015, the Company: a) Entered into a consulting agreement with an effective date of January 1, 2016 with the Company’s President and CEO whereby he will be compensated at a nominal amount of $1 for services through to December 31, 2016. The agreement also stipulates a termination fee that would pay the Company’s President and CEO $100,000 per year of service if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 per year of service plus 2.5% of the aggregate transaction value of the change of control. In addition, the agreement stipulates that he would be entitled to a bonus payment equal to 2.5% of the aggregate transaction value of an Application Sale or license of any Patent Rights, Patent Application Rights or products effected during the term of his agreement. He is also entitled to 5,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (granted subsequent to yearend). The options vest in equal instalments on a quarterly basis beginning March 31, 2016. b) Entered into a consulting agreement with an effective date of January 1, 2016 with the Company’s CFO whereby she will compensated at a monthly fee of $6,000 for services through to December 31, 2016. The agreement also stipulates a termination fee that would pay the Company’s CFO $36,000 if terminated without cause or $72,000 upon termination due to a change of control event. She is also entitled to 4,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (granted subsequent to yearend). The options vest in equal instalments on a quarterly basis beginning March 31, 2016. c) Entered into a consulting agreement with an effective date of January 1, 2016 whereby the Company would pay the consultant $7,000 per month for providing research and development services. The consultant is also entitled to 5,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (granted subsequent to yearend). The options vest in equal instalments on a quarterly basis beginning March 31, 2016. d) Entered into a directorship agreement with an effective date of January 1, 2016 with a director of the Company. Pursuant to the agreement, the director will be issued 1,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (granted subsequent to yearend). The options vest in equal instalments on a quarterly basis beginning March 31, 2016. e) On March 1, 2016, the Company issued 100,000 shares of common stock of the Company to a consultant for services pursuant to a consulting agreement (Note 13(b)).

2. Summary of Significant Acc22

2. Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements [Abstract]
Basis of Presentation	The accompanying financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and are expressed in United States dollars.
Use of Estimates	Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued and deferred income taxes.
Cash	Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.
Fair Value of Financial Instruments	Financial instruments, including cash, accounts payable and accrued liabilities, short-term loans and convertible note payable are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions) Level 1 inputs are used to measure cash. At December 31, 2015 there were no other assets or liabilities subject to additional disclosure.
Income Taxes	The Company accounts for income taxed following the assets and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.
Intangible assets - patent and patent application costs	The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred. As at December 31, 2015, the Company does not hold any intangible assets with indefinite lives. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company’s patents, whereas no amortization has been recognized on the patent application costs as at December 31, 2015.
Research and Development Costs	Research and development costs are expensed as incurred.
Loss per Share and Potentially Dilutive Securities	Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 14,600,000 stock options (December 31, 2014 - nil), 8,700,000 warrants (December 31, 2014 – 5,200,000) and debt convertible into nil common shares (December 31, 2014 – 400,000) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.
Share-Based Compensation	The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model. The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance. The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 “Stock-Based Transactions with Nonemployees””, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.
Common stock	Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty’s performance is complete. Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.
Related Party Transactions	A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.
Recent Accounting Pronouncements	In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessment of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is substantial doubt about the entity’s ability to continue as a going concern. The requirement is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s financial statements.

8. Common Shares Issued for S23

8. Common Shares Issued for Services (Tables)	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements [Abstract]
Schedule of Stock Incentive Plan, Issuances	2015 Number Value Total February 2015 1,000,000 $ 0.04 $ 40,000 June 2015 100,000 0.07 7,000 September 2015 100,000 0.07 7,000 September 2015 300,000 0.05 15,000 December 2015 100,000 0.07 7,000 December 2015 2,000,000 0.05 100,000 3,600,000 $ 176,000 2014 Number Value Total January 2014 25,550,000 $ 0.01 $ 255,500 June 2014 50,000 0.02 1,000 25,600,000 $ 256,500

9. Stock Options (Tables)

9. Stock Options (Tables)	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity	Number of Weighted Average Weighted Average Weighted Average $ $ (Years) Outstanding, December 31, 2013 and 2014 - - - Options granted 14,600,000 0.05 0.03 Outstanding, December 31, 2015 14,600,000 0.05 0.03 3.09
Schedule of valuation assumptions for options	For the year ended December 31, 2015 Risk-free interest rate 0.90 % Dividend yield 0.00 % Expected stock price volatility 125.00 % Expected forfeiture rate 0.00 % Expected life 4.50 years
Schedule of options by exercise price	Expiry date Exercise Price Number of Outstanding Number of Options $ March 12, 2016 0.10 1,000,000 750,000 February 25, 2017 0.04 2,000,000 - February 24, 2018 0.05 1,000,000 1,000,000 February 25, 2020 0.04 4,000,000 4,000,000 February 28, 2020 0.04 5,000,000 5,000,000 June 30, 2017 0.10 1,000,000 1,000,000 June 30, 2018 0.10 600,000 600,000 14,600,000 12,350,000

10. Warrants (Tables)

10. Warrants (Tables)	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements [Abstract]
Schedule of Warrant Activity	Number of Weighted Balance, December 31, 2013 21,300,000 $ 0.03 Issued 4,700,000 0.07 Expired (20,800,000 ) 0.02 Balance, December 31, 2014 5,200,000 0.09 Issued 11,000,000 0.07 Expired (2,500,000 ) 0.05 Exercised (5,000,000 ) 0.04 Balance, December 31, 2015 8,700,000 $ 0.11
Schedule of Stockholders' Equity Note, Warrants or Rights	Number of Warrants Exercise Price ($) Expiry Date 1,600,000 0.10 January 1 , 2016* 300,000 0.05 January 1 , 2016* 300,000 0.15 January 1 , 2016* 500,000 0.25 November 8, 2018 6,000,000 0.10 April 22, 2020 8,700,000

12. Related Party Transaction26

12. Related Party Transactions and Balances (Tables)	12 Months Ended
	Dec. 31, 2015
Related Party Transactions And Balances Tables
Schedule of related party transactions	December 31, 2015 December 31, 2014 Clarence Smith (CEO) Accounts payable and accrued liabilities $ 327 $ 129,592 Short-term loans $ nil $ 20,000 Convertible note payable $ nil $ 100,000 Susan Woodward (CFO) Accounts payable and accrued liabilities $ nil $ 12,000

2. Summary of Significant Acc27

2. Summary of Significant Accounting Policies (Details Narrative) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	0	400,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	8,700,000	5,200,000
Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	14,600,000	0

5. Intangible Assets (Details N

5. Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Intangible Assets Details Narrative
Amortization expense	$ 1,500

6. Short-Term Loans (Details Na

6. Short-Term Loans (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Short-term loans	$ 0	$ 63,250
Accretion		2,630
Issued units to settle loan		$ 25,000
Issued units to settle loan		2,500,000
Chief Executive Officer [Member]
Short-term loans	$ 60,250

7. Convertible Note Payable (De

7. Convertible Note Payable (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Notes to Financial Statements [Abstract]
Accrued interest include accounts payable and accrued liabilities		$ 84,000
Issuance of common stock to settle		3,840,000
Fair value of the shares		$ 192,000
Fair value of the shares per share		$ 0.05
Gain on settlement on loan		$ 192,000
Stipulated the payment	$ 161,750
Common stock conversion shares	1,250,000
Common stock conversion price per share	$ 0.08
Advances		23,500
Short-term loans outstanding		$ 90,000

8. Common Shares Issued for S31

8. Common Shares Issued for Services (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Number of Shares issued to non-employee consultants | shares	3,600,000	25,600,000
Total	$ 176,000	$ 256,500
February 2015 [Member]
Number of Shares issued to non-employee consultants | shares	1,000,000
Value per Share	$ 0.04
Total	$ 40,000
June 2015 [Member]
Number of Shares issued to non-employee consultants | shares	100,000
Value per Share	$ 0.07
Total	$ 7,000
September 2015 [Member]
Number of Shares issued to non-employee consultants | shares	100,000
Value per Share	$ 0.07
Total	$ 7,000
September 2015 [Member]
Number of Shares issued to non-employee consultants | shares	300,000
Value per Share	$ 0.05
Total	$ 15,000
December 2015 [Member]
Number of Shares issued to non-employee consultants | shares	100,000
Value per Share	$ 0.07
Total	$ 7,000
December 2015 [Member]
Number of Shares issued to non-employee consultants | shares	2,000,000
Value per Share	$ 0.05
Total	$ 100,000
January 2014 [Member]
Number of Shares issued to non-employee consultants | shares		25,550,000
Value per Share		$ 0.01
Total		$ 255,500
June 2014 [Member]
Number of Shares issued to non-employee consultants | shares		50,000
Value per Share		$ 0.02
Total		$ 1,000

9. Stock Options (Details)

9. Stock Options (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Notes to Financial Statements [Abstract]
Outstanding, beginning | shares
Options granted | shares	14,600,000
Outstanding, ending | shares	14,600,000
Weighted average exercise price beginning balance
Weighted Average Exercise Price, granted	$ 0.05
Weighed average exercise price ending balance	$ 0.05
Weighted Average Fair Value, beginning
Weighted Average Fair Value, granted	$ 0.03
Weighted Average Fair Value, ending	$ 0.03
Weighted Average Remaining Life	3 years 1 month 2 days

9. Stock Options (Details 1)

9. Stock Options (Details 1)	12 Months Ended
	Dec. 31, 2015
Stock Options Details 1
Risk-free interest rate	0.90%
Dividend yield	0.00%
Expected stock price volatility	125.00%
Expected forfeiture rate	0.00%
Expected life	4 years 6 months

9. Stock Options (Details 2)

9. Stock Options (Details 2) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Weighed average exercise price ending balance	$ 0.05
Outstanding, ending	14,600,000
Number of options exercisable	12,350,000
March 12, 2016
Weighed average exercise price ending balance	$ 0.10
Outstanding, ending	1,000,000
Number of options exercisable	750,000
February 25, 2017
Weighed average exercise price ending balance	$ 0.04
Outstanding, ending	2,000,000
Number of options exercisable
February 24, 2018
Weighed average exercise price ending balance	$ 0.05
Outstanding, ending	1,000,000
Number of options exercisable	1,000,000
February 25, 2020
Weighed average exercise price ending balance	$ 0.04
Outstanding, ending	4,000,000
Number of options exercisable	4,000,000
February 28, 2020
Weighed average exercise price ending balance	$ 0.04
Outstanding, ending	5,000,000
Number of options exercisable	5,000,000
June 30, 2017
Weighed average exercise price ending balance	$ 0.10
Outstanding, ending	1,000,000
Number of options exercisable	1,000,000
June 30, 2018
Weighed average exercise price ending balance	$ 0.10
Outstanding, ending	600,000
Number of options exercisable	600,000

9. Stock Options (Details Narra

9. Stock Options (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Aggregate intrinsic value	$ 350,000	$ 0
Weighted average fair value of stock options granted per share	$ 0.03
Common Stock [Member]
Common stock granted	2,000,000
Options [Member]
Common stock granted	1,600,000
Weighted average fair value of stock options granted per share	$ 0.05	$ 0

10. Warrants (Details)

10. Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Outstanding, beginning
Outstanding, ending	14,600,000
Weighted average exercise price beginning balance
Weighted average exercise price warrants issued	$ 0.05
Weighed average exercise price ending balance	$ 0.05
Warrant
Outstanding, beginning	5,200,000	21,300,000
Warrants issued during period	11,000,000	4,700,000
Warrants expired	(2,500,000)	(20,800,000)
Warrants Exercised	(5,000,000)
Outstanding, ending	8,700,000	5,200,000
Weighted average exercise price beginning balance	$ 0.09	$ 0.03
Weighted average exercise price warrants issued	0.07	0.07
Weighted average exercise price warrants expired	0.05	0.02
Weighted average exercise price warrants Exercised	0.04
Weighed average exercise price ending balance	$ 0.11	$ 0.09

10. Warrants (Details 1)

10. Warrants (Details 1)	Dec. 31, 2015$ / sharesshares
Number of Warrants	8,700,000
Warrants Expiring January 1 , 2016
Number of Warrants	1,600,000
Warrant Exercise Price | $ / shares	$ 0.10
Warrants B Expiring January 1 , 2016
Number of Warrants	300,000
Warrant Exercise Price | $ / shares	$ 0.05
Warrants C Expiring January 1 , 2016
Number of Warrants	300,000
Warrant Exercise Price | $ / shares	$ 0.15
Warrants Expiring November 8, 2018
Number of Warrants	500,000
Warrant Exercise Price | $ / shares	$ 0.25
Warrants Expiring April 22, 2020
Number of Warrants	6,000,000
Warrant Exercise Price | $ / shares	$ 0.10

12. Related Party Transaction38

12. Related Party Transactions and Balances (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Accounts payable and accrued liabilities	$ 45,388	$ 270,893
Short-term loans	0	63,250
Clarence Smith (CEO)
Accounts payable and accrued liabilities	$ 327	129,592
Short-term loans		20,000
Convertible note payable		100,000
Susan Woodward (CFO)
Accounts payable and accrued liabilities
Susan Woodward (CFO)
Accounts payable and accrued liabilities		$ 12,000

14. Income Taxes (Details Narra

14. Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes Details Narrative
Income tax losses	$ 26,400,000	$ 25,800,000
Deferred tax asset tax loss carry forward	$ 9,000,000	$ 8,800,000